<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01128855</url>
  </required_header>
  <id_info>
    <org_study_id>114118</org_study_id>
    <nct_id>NCT01128855</nct_id>
  </id_info>
  <brief_title>A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects</brief_title>
  <acronym>DEMAND I</acronym>
  <official_title>A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Single Subcutaneous Injections of GSK2402968 in Non-ambulant Subjects With Duchenne Muscular Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is investigate the pharmacokinetics, safety and tolerability of
      single subcutaneous administration of GSK2402968 in non-ambulant boys with Duchenne muscular
      dystrophy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 12, 2010</start_date>
  <completion_date type="Actual">October 25, 2011</completion_date>
  <primary_completion_date type="Actual">October 25, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Pharmacokinetic Variables:AUC, Cmax,t-max, CL/F</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Injection Site Reactions</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Muscular Dystrophies</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 mg/kg GSK2402968 / placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 mg/kg GSK2402968 / placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 mg/kg GSK2402968 / placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 mg/kg GSK2402968 / placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>3 mg/kg GSK2402968</intervention_name>
    <description>Weekly subcutaneous injection</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6 mg/kg GSK2402968</intervention_name>
    <description>Weekly subcutaneous injection</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>9 mg/kg GSK2402968</intervention_name>
    <description>Weekly subcutaneous injection</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>12 mg/kg GSK2402968</intervention_name>
    <description>Weekly subcutaneous injection</description>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Weekly Placebo</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Duchenne muscular dystrophy resulting from a mutation in the DMD gene, confirmed by a
             sponsor approved DNA diagnostic technique covering all DMD gene exons, including but
             not limited to MLPA (Multiplex Ligation-dependent Probe Amplification), CGH
             (Comparative Genomic Hybridisation), SCAIP (Single Condition Amplification/Internal
             Primer) or H-RMCA (High-Resolution Melting Curve Analysis), and correctable by
             treatment with GSK2402968.

          -  Age 9 years old or greater at Screening;

          -  Male;

          -  Non-ambulant (at least 1 year in a wheelchair) within the last 4 years;

          -  Life expectancy at least three years;

          -  Willingness and ability to comply with all protocol requirements and procedures;

          -  QTc &lt;450msec (based on single or average QTc value of triplicate ECGs obtained over a
             brief recording period). Note: QTc may be either QTcB or QTcF, machine read or manual
             overread;

          -  Subjects must be willing to use adequate contraception (condoms or abstinence), from
             Screening until at least 5 months after the last dose of study drug;

          -  Informed assent and/or consent in writing signed by the subject and/or parent(s)/legal
             guardian (according to local regulations).

        Exclusion Criteria:

          -  Any additional mutation (such as an additional missing exon for DMD) that cannot be
             treated with GSK2402968;

          -  Current or history of liver or renal disease;

          -  Acute illness within 4 weeks of anticipated administration of study medication, which
             may interfere with study assessments;

          -  Use of anticoagulants, antithrombotics or antiplatelet agents, previous treatment with
             investigational drugs, idebenone or other forms of Coenzyme Q10, within 6 months of
             the first administration of study medication;

          -  Start of glucocorticosteroids within 6 months or non-stable use of
             glucocorticosteroids within 3 months of the anticipated first administration of study
             medication;

          -  Positive hepatitis B surface antigen (HbsAg), hepatitis C antibody test (HCV), or
             human immunodeficiency virus (HIV) test at Screening;

          -  Symptomatic cardiomyopathy;

          -  Use of alcohol from Screening through to the 1 month Follow-up visit ;

          -  Any Child in Care.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://gsk-clinicalstudyregister.com/study/114118?search=study&amp;study_ids=114118#rs</url>
    <description>Results for study 114118 can be found on the GSK Clinical Study Register.</description>
  </link>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2010</study_first_submitted>
  <study_first_submitted_qc>May 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne</keyword>
  <keyword>Duchenne Muscular Dystrophy</keyword>
  <keyword>DMD</keyword>
  <keyword>968</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

